| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454508 | Lung Cancer | 2016 | 4 Pages |
Abstract
This is the first clinical study of EP4 expression in lung cancer. There was a significant correlation between OS and nuclear EP4 expression, indicating that this is a potential therapeutic target. Studies with AT-007, a specific inhibitor of EP4, are planned to commence this year.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Neha M.D., Ph.D., Paul N. M.D., Amy M. Ph.D., Josephine L. M.D., Martin J. M.D.,